As part of our monthly news service we would like to make you aware of the CML publications of the month. From the many papers published every month Professor Timothy Hughes has selected topical, interesting papers for your perusal that also include interesting articles on pediatric CML and from low- and middle-income countries. Due to the Climb for a cure Annapurna 2023 this is an unusual 2-months highlight of CML papers.

Read Professor Hughes' CML publications of the month: October - November 2023

Clinical CML papers

• Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia
  Efficace F et al. Cancer, October 2023 (epub ahead of print)
• Spontaneous remission in a patient with chronic myeloid leukemia: A Case Report
  Alshurufa A et al. Case Rep Oncol, October 2023 – open access publication
• Low-dose dasatinib (50 mg daily) frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia: 5-year follow-up results
  Gener-Ricos C et al. Clin Lymphoma Myeloma Leuk, October 2023
• Revisiting six established practices in the treatment of chronic myeloid leukemia - Review
  Kantarjian HM et al. Lancet Haematol, October 2023
• Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy
  Khadadah FM et al. Leuk Res, October 2023
• Despite warnings, co-medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004, a novel oral dasatinib formulation, provides reduced pH-dependence, minimizing undesirable drug-drug interactions
  Larfors G et al. Eur J Haematol, October 2023 – open access publication
  
• European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia
  Cross NCP et al. Leukemia, November 2023 – open access publication
• Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO Study
  Zambrotta GPM et al. Am J Hematol, November 2023 – open access publication
• Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia:
  Results from the phase 4 BYOND study
  Rosti G et al. Leukemia, November 2023 (epub ahead of print) – open access publication
• What is the impact of failing to achieve TKI therapy milestones in chronic myeloid leukemia?
  Kantarjian HM Leukemia, November 2023
• The new systematic coronary risk evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib and ponatinib
  Mulas O et al. Ann Hematol, November 2023
• Effect of BCR::ABL1 transcript type and droplet digital polymerase chain reaction on successful treatment-free remission in chronic myeloid leukemia patients who discontinued tyrosine kinase inhibitor
  Park H et al. Ther Adv Hematol, November 2023 – open access publication
  
• Frequency and prognostic influence of ASXL1 mutations and its potential association with BCR-ABL1 transcript type and smoke in chronic myeloid leukemia patients
  Rafiq Mohammed A et al. Gene, November 2023

Scientific CML papers

• Deciphering potential molecular signatures to differentiate acute myeloid leukemia (AML) with BCR::ABL1 from chronic myeloid leukemia (CML) in blast crisis
  Boucher L et al. Int J Mol, October 2023 – open access publication
• Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation
  Huuhtanen J et al. Leukemia, November 2023 (epub ahead of print) – open access publication
  

Pediatric CML papers

• Continuous therapy response references for BCR::ABL1 monitoring in pediatric chronic myeloid leukemia
  Volz C et al. Sci Rep, October 2023 – open access publication
• Chronic myeloid leukemia (CML) in children and adolescents – Clinicopathological findings
  Nevejan L et al. Eur J Haematol, November 2023 (epub ahead of print)
• Physiologically based pharmacokinetics modelling of nilotinib for drug-drug interactions, pediatric patients, and pregnancy and lactation
  Liu XI et al. J Clin Pharmacol, November 2023 (epub ahead of print)

LMIC CML papers

• Long-term follow-up in patients with chronic myeloid leukemia treated with ponatinib in a real-world cohort: Safety and efficacy analysis
  Mela Osorio MJ et al. Clin Lymphoma Myeloma Leuk, October 2023 (epub ahead of print)
• Long-term results of imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: National Multicenter perspective study
  Savaş EM et al. Turk J Haematol, October 2023 (epub ahead of print) – open access publication

COVID-19 + CML

• Regular humoral and cellular immune responses in individuals with chronic myeloid leukemia who received a full vaccination schedule against COVID-19
  Rodríguez-Mora S et al. Cancers(Basel), October 2023 – open access publication